Quick Takeaways
- Redmile Group, LLC filed SCHEDULE 13G/A for Immunome, Inc. Common Stock, $0.0001 Par Value (IMNM).
- Disclosed ownership: 6.2%.
- Date of event: 31 Mar 2025.
Redmile Group, LLC - 31 Mar 2025 SCHEDULE 13G/A Report for Immunome, Inc. Common Stock, $0.0001 Par Value (IMNM)
- Filing Manager
- Redmile Group, LLC
- Reporting Manager
- Redmile Group, LLC
- Symbol
- IMNM
- Shares outstanding
- 86,470,758 shares
- Disclosed Ownership
- 5,361,187 shares
- Ownership
- 6.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 21:01:01 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 17 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Redmile Group, LLC disclosed 6.2% ownership in Immunome, Inc. Common Stock, $0.0001 Par Value (IMNM) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2025, 21:01.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 6.2% | 5,361,187 | 0 | 5,361,187 | /s/ Jeremy C. Green | Managing Member | |
| Jeremy C. Green | 6.2% | 5,361,187 | 0 | 5,361,187 | /s/ Jeremy C. Green | Jeremy C. Green | |
| Redmile Biopharma Investments III, L.P. | 4.5% | 3,879,415 | 0 | 3,879,415 | /s/ Jeremy C. Green | Managing Member of Redmile Biopharma Investments III (GP), LLC, general partner of Redmile Biopharma Investments III, L.P. |